BCL2A1 neoepitope–elicited cytotoxic T lymphocytes are a promising individualized immunotherapy of pancreatic cancer

S Lin, J Hong, S Wu, C Zhu, F Liu, W Lin… - Journal of Leukocyte …, 2024 - academic.oup.com
Conventional treatments have shown a limited efficacy for pancreatic cancer, and
immunotherapy is an emerging option for treatment of this highly fatal malignancy …
相关文章

BCL2A1 neoepitopes-elicited cytotoxic T lymphocytes are a promising individualized immunotherapy of pancreatic cancer

S Lin, J Hong, S Wu, C Zhu, F Liu, W Lin… - Journal of leukocyte … - pubmed.ncbi.nlm.nih.gov
Conventional treatments have shown a limited efficacy for pancreatic cancer, and
immunotherapy is an emerging option for treatment of this highly fatal malignancy …

BCL2A1 neoepitopes-elicited cytotoxic T lymphocytes are a promising individualized immunotherapy of pancreatic cancer.

S Lin, J Hong, S Wu, C Zhu, F Liu, W Lin… - Journal of Leukocyte …, 2024 - europepmc.org
Conventional treatments have shown a limited efficacy for pancreatic cancer, and
immunotherapy is an emerging option for treatment of this highly fatal malignancy …